Tandem Diabetes Care, Inc. (TNDM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 499 | 703 | 801 | 748 | 940 | 1,015 | 1,041 | 1,072 |
| Operating profit | $m | -78 | -43 | ||||||
| Net profit | $m | -34 | 16 | -95 | -223 | -96 | -205 | -63 | -44 |
| EPS reported | $ | -3.04 | -0.93 | ||||||
| Operating cashflow per share | $ | -0.14 | -0.08 | ||||||
| Capex per share | $ | 0.30 | 0.31 | ||||||
| FCF per share | $ | -0.44 | -0.39 | ||||||
| Free cash flow | $m | -30 | -27 | ||||||
| Net debt | $m | 17 | 147 | ||||||
| Book value equity | $m | 155 | 130 | ||||||
| Book value per share | $ | 2.31 | 1.91 | ||||||
| Number of shares | m | 67.29 | 68.4 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 9.53 | 11.34 | ||||||
| P/S LTM | x | 1.46 | 1.42 | ||||||
| P/FCF LTM | x | -49.85 | -55.56 | ||||||
| EV/EBITDA LTM | x | -10.49 | -60.46 | ||||||
| EV/Sales LTM | x | 1.81 | 2.14 | ||||||
| Earnings Yield LTM | % | -13.84% | -4.08% | ||||||
| FCF Yield | % | -2.01% | -1.80% | ||||||
| Quality | |||||||||
| ROE | % | -131.93% | -45.97% | ||||||
| ROIC | % | -11.88% | -4.77% | ||||||
| Operating margin | % | -7.70% | -4.13% | ||||||
| Gross margin | % | +52.31% | +56.01% | ||||||
| FCF/Sales | % | -2.92% | -2.56% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +7.93% | +10.77% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.07 | -0.04 | ||||||
| Net Debt/EBITDA | x | -2.03 | -22.32 | ||||||
| EBIT/Net interest | x | -9.88 | -5.23 | ||||||
| Net debt/market cap | % | +20.96% | +46.25% | ||||||
| Net debt/Equity | x | 0.11 | 1.12 | ||||||
| Gross debt/equity | x | 2.86 | 5.67 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Tandem Diabetes Care, Inc. (TNDM)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free